Seattle Genetics was founded in 1998, and since 2001 the company’s stock has been publicly traded on Nasdaq under the symbol SGEN. Our leadership in antibody-drug conjugates (ADCs) and focus on innovative, targeted therapies for cancer, has resulted in one approved drug and a robust pipeline of programs in clinical development for lymphoma, leukemia, urothelial (bladder) and breast cancer.
04/26/18 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delay
|Common Stock CUSIP||812578 102|
|Fiscal Year||Jan. 1 - Dec. 31|